Clinical Trial Update: A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating safety and efficacy of ACT001 in combination with anti-PD-1 in patients with surgically accessible recurrent glioblastoma multiforme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• ACT001
• Anti-PD-1

Snippet

Sponsor: Accendatech USA Inc. | Conditions: Recurrent Glioblastoma Multiforme(GBM) | Phase 1, Phase 2 | Status: UNKNOWN